Form 4 Filing for Immunome Inc. - Rosett Max

This filing details transactions by Rosett Max, Chief Financial Officer of Immunome Inc. On July 23, 2026, Rosett Max acquired 47,250 shares of Common Stock via restricted stock units (RSUs), bringing the total post-transaction shares to 101,287. Additionally, an Employee Stock Option to acquire 94,500 shares of Common Stock was granted, with 25% vesting annually starting July 23, 2027, and the remainder vesting monthly thereafter. The option has an exercise price of $22.01 and an expiration date of July 22, 2036. These transactions are marked as direct ownership.